This 2-hour, interactive symposium will provide an opportunity for participants to evaluate the potential clinical value of recent large-scale randomized clinical trials on the management of patients at high risk of having atherosclerotic cardiovascular disease (ASCVD) events. Over the past year, many high quality ASCVD outcomes trials have been published, and their impact on clinical management is already taking shape. Amidst this progress in translational science, clinicians have several important issues to address so that the full benefit of the science is realized in clinical management.

The program will relate these recent ASCVD outcomes trials results and address important controversies arising from them. 

A rigorous and thorough review of the Level A cardiovascular outcomes trials (CVOTs) will be presented. Additionally, 3 controversial issues will be treated with 2 perspectives by experts on the topics, allowing different points to be emphasized and showing where there may not be unanimity. For each issue, the audience will have the opportunity to decide which expert made the most compelling argument.

The faculty will consist of internationally recognized experts in CVOTs and CVD risk reduction. The symposium will feature a unique format that is highly interactive, provides multiple perspectives, and allows significant audience participation, with the goal of improving competence and confidence in clinical management.

This event is not part of the official Scientific Sessions as planned by the AHA Committee on Scientific Sessions Programming.